Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
An acute lymphoblastic leukemia occurring during childhood. The majority of cases are B-acute lymphoblastic leukemias. Approximately 15% of the cases are T-acute lymphoblastic leukemias.
Biomarker and diagnostic research for childhood acute lymphoblastic leukemia has been reported in the published literature.
96 clinical trials registered, 51 recruiting. Interventions under study include other interventions, drug therapy, medical devices, and biologic therapy. Pipeline includes 5 PHASE4, 2 PHASE3, 12 PHASE2. Research is sponsored by a mix of industry and academic institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT05700799](https://clinicaltrials.gov/study/NCT05700799) |
Data assembled from 3 of 12 sources · Last updated Nov 3, 2026, 3:00 PM UTC
Program availability and eligibility requirements are set by each foundation. Contact them directly to learn more about your options.
Claim this page and your organization will be listed here for patients and families to find.
Genetic and Rare Diseases Info Center
HEalth Advocate for Liver Transplant - Pilot |
NA |
University of California, San Francisco |
RECRUITING |
[NCT04794296](https://clinicaltrials.gov/study/NCT04794296) | Recommendations for the Treatment of Children With Acute Lymphoblastic Leukemia in the GFAOP | — | French Africa Pediatric Oncology Group | RECRUITING |
[NCT06508775](https://clinicaltrials.gov/study/NCT06508775) | Long-Term Follow-up of Patients Treated With Miltenyi Cell and Gene Therapies | NA | Miltenyi Biomedicine GmbH | RECRUITING |
[NCT06184009](https://clinicaltrials.gov/study/NCT06184009) | Treatment of Newly Diagnosed High Risk Pediatric Acute Lymphoblastic Leukemia | PHASE2 | Jae Wook Lee | RECRUITING |
[NCT06771830](https://clinicaltrials.gov/study/NCT06771830) | Evaluation of Pediatric eCART Implementation | NA | University of Wisconsin, Madison | RECRUITING |
432 publications have been identified in PubMed for childhood acute lymphoblastic leukemia. Research spans Epidemiology / Natural History (29%), Review / Meta-Analysis (25%), and Basic Science / Preclinical (18%).
Research Type | Count | % of Total |
|---|---|---|
Disease patterns and progression | 125 | 29% |
Research summaries | 107 | 25% |
Laboratory research | 76 | 18% |
Testing and diagnosis research | 40 | 9% |
Clinical study results | 38 | 9% |
Patient case studies | 26 | 6% |
New treatment approaches | 11 | 3% |
Other research | 9 | 2% |
Mikkelsen T (2026). [PMID: 41361660](https://pubmed.ncbi.nlm.nih.gov/41361660/). *Leukemia*. [Basic Science / Preclinical]
Burkitbayev Z (2026). [PMID: 42265862](https://pubmed.ncbi.nlm.nih.gov/42265862/). *HLA*. [Epidemiology / Natural History]
Colomer-Molera M (2026). [PMID: 42159582](https://pubmed.ncbi.nlm.nih.gov/42159582/). *J Gen Physiol*. [Basic Science / Preclinical]
Correa BT (2026). [PMID: 41768259](https://pubmed.ncbi.nlm.nih.gov/41768259/). *Front Oncol*. [Review / Meta-Analysis]
Cassaday RD (2026). [PMID: 41532388](https://pubmed.ncbi.nlm.nih.gov/41532388/). *Am J Hematol*. [Review / Meta-Analysis]
Ahmed A (2026). [PMID: 42152197](https://pubmed.ncbi.nlm.nih.gov/42152197/). *J Coll Physicians Surg Pak*. [Epidemiology / Natural History]
Othman T (2026). [PMID: 42150924](https://pubmed.ncbi.nlm.nih.gov/42150924/). *Clin Lymphoma Myeloma Leuk*. [Review / Meta-Analysis]
Fishchuk L (2026). [PMID: 41788072](https://pubmed.ncbi.nlm.nih.gov/41788072/). *Exp Oncol*. [Basic Science / Preclinical]
Haider MZ (2026). [PMID: 32809524](https://pubmed.ncbi.nlm.nih.gov/32809524/). *Unknown Journal*. [Basic Science / Preclinical]
Gil JV (2026). [PMID: 41820162](https://pubmed.ncbi.nlm.nih.gov/41820162/). *Blood Rev*. [Review / Meta-Analysis]
AI-curated news mentioning childhood acute lymphoblastic leukemia
Updated Oct 13, 2026
A study compares a pediatric-inspired USC-ALL regimen to hyper-CVAD in adults with Philadelphia-negative and Philadelphia-like acute lymphoblastic leukemia. The findings contribute to understanding treatment efficacy in this patient population.
A recent study investigates the necessity of antifungal prophylaxis in adults undergoing treatment for acute lymphoblastic leukemia. The retrospective cohort study highlights infectious complications associated with the treatment, providing insights for clinical practice.
Vironexis reports complete and durable responses in relapsed/refractory acute lymphoblastic leukemia (ALL) patients treated with VNX-101. The therapy has received FDA Fast Track, Orphan Drug, and Rare Pediatric Disease designations, highlighting its potential in addressing this critical patient population.
A study from a tertiary care cancer center in a lower-middle-income country reports on the outcomes of pediatric precursor B cell acute lymphoblastic leukemia. The findings contribute to understanding treatment efficacy and patient management in resource-limited settings.
Dr. Emily Curran advocates for decentralized clinical trials to improve access for acute lymphoblastic leukemia (ALL) patients, particularly those with impaired kidney function who are often excluded from traditional trials. She emphasizes the need for stronger community-academic ties to ensure that real-world treatment decisions are informed by trial data.